Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

43

Revenue 2017

Perjeta

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Perjeta was produced by Roche.

NICE rejects Roche's Kadcyla as "unaffordable"

NICE rejects Roche's Kadcyla as The company is facing the threat of biosimilar competition to Herceptin later this year and had its Perjeta (pertuzumab) breast cancer drug rejected by NICE in draft guidance published in 2013.

Pharma's winners and losers in 2013

Pharma's winners and losers in 2013 well as emerging therapies such as breast cancer therapies Perjeta (pertuzumab) and Kadcyla (trastuzumab emtansine).

Roche signs biologics partnership with Samsung

Roche signs biologics partnership with Samsung Roche's biologics portfolio includes the cancer drugs Kadcyla (trastuzumab emtansine) and Perjeta (pertuzumab), which launched this year and brought in 191m Swiss francs (about $214m) in the first half of

Roche invests $879m in its biologics future

Roche invests $879m in its biologics future If licensed obinutuzumab would join a portfolio of biologics that includes RoActemra (tocilizumab), Kadcyla (trastuzumab emtansine) and Perjeta (pertuzumab).

FDA gives green light to Roche for early Perjeta in breast cancer

FDA gives green light to Roche for early Perjeta in breast cancer A new approval pathway has made Perjeta available to people with HER2-positive early breast cancer several years earlier than previously possible.”. ... Roche also confirmed it was discussing the option of submitting Perjeta in the neoadjuvant setting

[ Previous 5 results ] 6 7 8 9 10 11 12 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics